Chong Kun Dang Pharmaceutical Corp.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Safety and Pharmacokinetic Profile of CKD-581
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 39
- Registration Number
- NCT01580371
- Locations
- 🇰🇷
ASAN Medical Center, Seoul, Korea, Republic of
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: CKD-516 inj.
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 21
- Registration Number
- NCT01560325
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
CKD-828 S-Amlodipine Non-Responder Trial
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 187
- Registration Number
- NCT01501253
- Locations
- 🇰🇷
Seoul St. Mary's hospital, The catholic university of Korea, Seoul, Korea, Republic of
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 164
- Registration Number
- NCT01497873
- Locations
- 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇰🇷Chungbuk University Hospital, Daegu, Korea, Republic of
🇰🇷Keimyung University Dongsan Center, Daegu, Korea, Republic of
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Fixed dose combination of clopidogrel/aspirin
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2011-12-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT01496261
- Locations
- 🇰🇷
Inje University Pusan Paik Hospital, Jin-gu, Pusan, Korea, Republic of
CKD-828 Telmisartan Non-Responder Trial
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 183
- Registration Number
- NCT01426100
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
🇰🇷Ewha Womans University Hospital, Seoul, Korea, Republic of
🇰🇷Daegu Catholic University Medical Center, Daegu, Korea, Republic of
Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT01369472
- Locations
- 🇰🇷
Asan Medcial Center, Songpa-gu, Seoul, Korea, Republic of
CKD-828 Drug Interaction Study (Telmisartan)
- Conditions
- Healthy Male Volunteers
- Interventions
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2011-09-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT01356017
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
CKD-828 Drug Interaction Study (S-amlodipine)
- Conditions
- Healthy Male Volunteers
- Interventions
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT01356043
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
CKD-828(80/2.5mg) Pharmacokinetic Study_2nd
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 67
- Registration Number
- NCT01352689